(firstQuint)Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency.

 Patients with hepatic insufficiency is an important subgroup of who receive EGFR TKIs.

 Phase I/II studies showed that Icotinib has good security.

 Based on the above considerations, this single-arm, open-label study is designed to evaluate the safety of icotinib 125mg three times daily for histologically or cytologically confirmed NSCLC patients with hepatic insufficiency.

.

 Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency@highlight

The purpose of this study is to determine whether Icotinib is efficient and safe in treating advanced non-small cell lung cancer (NSCLC) patients with hepatic insufficiency.

